Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Dermatology

RSS  

Articles

  • Pharmacology Update: Deferasirox Tablets for Oral Suspension (Exjade®)

    Following a priority review, the FDA has approved deferasirox, the first oral iron chelator for the treatment of chronic iron overload due to transfusions. It will be marketed by Novartis Pharmaceuticals as Exjade®.
  • Venous Thromboembolism: How Long to Treat?

    Patients who receive extended anticoagulation are protected from recurrent VTE while receiving long-term therapy. The clinical benefit is maintained after anticoagulation is discontinued, but the magnitude of the benefit is less pronounced.
  • Make Mine Espresso!

    Cola consumption, but not caffeine per se, was associated with increased risk of developing hypertension over a 12-year period.
  • Clinical Briefs By Louis Kuritzky, MD

    Doxycycline Hyclate 20 mg Tablets and Metronidazole 0.75% Topical Lotion in the Treatment of Rosacea; Left Atrial Radiofrequency Ablation During Mitral Valve Surgery for Continuous Atrial Fibrillation; Comorbid Depression with Mortality in Patients with DM
  • Exanatide: The New Shot for Diabetes

    A new injectable diabetes medication in the family of incretin mimetic drugs has been shown to be as effective as insulin in controlling average blood sugars in Type 2 diabetics who are difficult to control on oral medications, without as much associated weight gain.
  • CABG vs Stenting: Which is Better?

    A meta-analysis comparing percutaneous balloon angioplasty alone vs coronary artery bypass grafting (CABG) demonstrated no significant differences in mortality and nonfatal myocardial infarction (MI) however, a statistically significant benefit in terms of survival in favor of surgery1 was noted.
  • Imiquimod — It's Not Just for Genital Warts Anymore

    Imiquimod is safe and effective in the treatment of actinic keratoses.
  • Pharmacology Update: Nelarabine Injection (Arranon®)

    The FDA has approved nelarabine for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic leukemia (T-LBL). Nelarabine was approved under the FDAs accelerated approval program. It received an Orphan Designation because it is for a rare disease affecting less than 200,000 in the United States. Nelarabine is marketed by GlaxoSmithKline as Arranon®.
  • A Shingles Vaccine

    The use of an attenuated varicella zoster virus vaccine, many times more potent than that used in children for the prevention of chickenpox, was effective in the prevention of both herpes zoster and postherpetic neuralgia in individuals 60 years of age and older.
  • Weight a Minute!

    Death rates in the year after bariatric surgery were high (4.6%), and were higher for men, for those older than 65, and for those whose surgeon performed fewer than 35 such operations a year.